Correlative polymorphism of NAD(P)H: Quinone oxidoreductase (NQO1) with telomere shortening in colorectal cancer

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2749-2752

  Takagi, Sho ^a   Kinouchi, Yoshitaka ^a   Hiwatashi, Nobuo ^a   Hirai, Masashi ^a   Suzuki, Susumu ^a   Takahashi, Seiichi ^a   Negoro, Kenichi ^a   Obana, Nobuya ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; DT diaphorase; NAD(P)H: quinone oxidoreductase; NQO1; Polymorphism; Telomerase; Telomere

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ARTICLE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MUTATION; NAD(P)H DEHYDROGENASE (QUINONE); POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TELOMERASE; TELOMERE;

EID: 0036765920     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ernster L: DT-diaphorase: a historical review. Chem Scr 27A: 1-13, 1987.
2. Wattenberg LW: Chemoprevention of cancer. Cancer Res 45: 1-8, 1985.
3. Traver RD, Horikoshi T and Danenberg KD et al: NID(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52: 797-802, 1992.
4. Traver RD, Phillips RM and Gibson NW et al: A point mutation in both human lung and colon carcinoma cell lines leading to a loss of DT-diaphorase activity. Proc Am Assoc Cancer Res 36: 525, 1995.
5. Kuehl BL, Paterson JWE and Peacock JW et al: Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 72: 555-561, 1995.
6. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
7. Counter CM, Avilion AA and Le Feuvre CE et al: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921-1929, 1992.
8. Hastie ND and Allshire RC: Human telomeres: fusion and interstitial sites. Trends Genet 5: 326-331, 1989.
9. Harley CB: Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256: 271-282, 1991.
10. Hastie ND, Dempster M and Dunlop MG et al: Telomere reduction in human colorectal carcinoma and with ageing. Nature 346: 866-868, 1990.
11. Hall DB, Holmlin RE and Barton JK: Oxidative DNA damage through long-range electron transfer. Nature 382: 731-735, 1996.
12. von Zglinicki T, Saretzki G and Docke W et al: Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res 220: 186-193, 1995.
13. Mehle C, Ljungberg B and Roos G: Telomere shortening in renal cell carcinoma. Cancer Res 54: 236-241, 1994.
14. Counter CM, Botelho FM and Wang P et al: Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lympocytes. J Virol 68: 3410-3414, 1994.
15. Greider CW and Blackburn EH: The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51: 887-898, 1987.
16. Kim NW, Piatyszek MA and Prowse KR et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
17. Chadeneau C, Hay K and Hirte HW et al: Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 55: 2533-2536, 1995.
18. Takagi S, Kinouchi Y and Hiwatashi N et al: Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas. Cancer 86: 1431-1436, 1999.
19. Takagi S, Kinouchi Y and Hiwatashi N et al: Relationship between microsatellite instability and telomere shortening in human colorectal cancer. Dis Colon Rectum 43 (Suppl): s12-s17, 2000.
20. Traver RD, Siegel D and Beall HD et al: Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75: 69-75, 1997.
21. Eickelmann P, Schulz WA and Rohde D et al: Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler 375: 439-445, 1994.
22. Wright WE, Shay JW and Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23: 3794-3795, 1995.
23. Gaedigk A, Tyndale RF and Jurima-Romet M et al: NAD(P)H: quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8: 305-313, 1998.
24. Chen H, Lum A and Seifried A et al: Association of the NAD(P)H: quinone oxidoreductase 609C>T polymorphism with a decreased lung cancer risk. Cancer Res 59: 3045-3048, 1999.
25. Broccoli D, Smogorzewska A and Chong L et al: Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet 17: 231-235, 1997.
26. Shoji Y, Yoshinaga K and Inoue A et al: Quantification of telomerase activity in sporadic colorectal carcinoma: association with tumor growth and venous invasion. Cancer 88: 1304-1309, 2000.